Biotech »

Sirona Biochem CEO Belenkie resigns

Sirona Biochem CEO Belenkie resigns

Alpha Stox June 23, 2014 Comments Off

Mr. Christopher Hopton reports SIRONA ANNOUNCES RESIGNATION OF NEIL BELENKIE Neil Belenkie has resigned as chief executive officer of Sirona Biochem Corp. Mr. Belenkie has agreed to stay on with the company to assist

Read More »
Sirona Biochem’s Subsidiary, TFChem, Selected for UBISTART Tour 2014

Sirona Biochem’s Subsidiary, TFChem, Selected for UBISTART Tour 2014

Alpha Stox June 11, 2014 Comments Off

VANCOUVER, BC–(Marketwired – June 11, 2014) – Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that its subsidiary, TFChem, has been selected for participation in the UBISTART Tour

Read More »
Agility Health partner Border opens El Paso clinic

Agility Health partner Border opens El Paso clinic

Alpha Stox June 10, 2014 Comments Off

Mr. Wayne Shaw of Border Therapy reports AGILITY HEALTH PARTNER, BORDER THERAPY SERVICES, OPENS FOURTH LOCATION IN EAST EL PASO Agility Health Inc.’s partner, Border Therapy Services, has opened a new clinic on the

Read More »
iCo Therapeutics needs more data to understand iCo-007

iCo Therapeutics needs more data to understand iCo-007

Alpha Stox June 9, 2014 Comments Off

Mr. John Meekison reports ICO THERAPEUTICS ANNOUNCES TOP-LINE PRIMARY ENDPOINT DATA FROM ICO-007 PHASE 2 IDEAL STUDY IN DIABETIC MACULAR EDEMA iCo Therapeutics Inc. has provided top-line results related to the eight-month visual acuity

Read More »
ProMetic receives $5.6-million order from Octapharma

ProMetic receives $5.6-million order from Octapharma

Alpha Stox June 5, 2014 Comments Off

Mr. Pierre Laurin reports PROMETIC RECEIVES A $5.6 MILLION PURCHASE ORDER FROM OCTAPHARMA ProMetic Life Sciences Inc. has received a $5.6-million purchase order under its continuing supply agreement with Octapharma, a leading, Swiss, independent,

Read More »
Sirona licensee starts preclinical validation for drug

Sirona licensee starts preclinical validation for drug

Alpha Stox June 3, 2014 Comments Off

An anonymous director reports SIRONA BIOCHEM ANNOUNCES WANBANG BIOPHARMACEUTICAL’S LAUNCH OF PRE-CLINICAL VALIDATION Sirona Biochem Corp. licensee Wanbang Biopharmaceuticals has begun preclinical validation for Sirona Biochem’s second-generation SGLT2 inhibitor. To date, Sirona has received

Read More »
Sirona Biochem Expands Exclusive Skin Lightening License with Valeant Pharmaceuticals to Include AMBI and Kinerase

Sirona Biochem Expands Exclusive Skin Lightening License with Valeant Pharmaceuticals to Include AMBI and Kinerase

Alpha Stox May 29, 2014 Comments Off

Vancouver, British Columbia – May 29, 2014 – Sirona Biochem Corp. (TSX-V: SBM.V) (OTCQX: SRBCF) (FRANKFURT: ZSB) announces the expansion of its exclusive license with Valeant Pharmaceuticals (“Valeant”) for Sirona’s skin lightening compound TFC-849

Read More »
Sirona Biochem’s TFC-837 can extend cell life

Sirona Biochem’s TFC-837 can extend cell life

Alpha Stox May 23, 2014 Comments Off

Mr. Neil Belenkie reports SIRONA BIOCHEM’S ANTI-AGING GLYCOPROTEIN SUCCESSFULLY EXTENDS CELL LIFE IN SERUM DEPRIVATION STUDY Sirona Biochem Corp.’s anti-aging compound TFC-837 was proven to extend cell life with outstanding results in a 12-day

Read More »
SQI Diagnostics loses $956,000 in fiscal Q2

SQI Diagnostics loses $956,000 in fiscal Q2

Alpha Stox May 12, 2014 Comments Off

Mr. Andrew Morris reports SQI RECORDS FIRST REVENUES FROM SALES TO GLOBAL PHARMACEUTICAL CUSTOMERS SQI Diagnostics Inc. has released its financial and operational results for its fiscal second quarter ended March 31, 2014. “This

Read More »
ProMetic Life increases NantPro interest to 60%

ProMetic Life increases NantPro interest to 60%

Alpha Stox May 9, 2014 Comments Off

Mr. Pierre Laurin reports PROMETIC INCREASES ITS OWNERSHIP STAKE IN NANTPRO BIOSCIENCES, LLC (“NANTPRO”) ProMetic Life Sciences Inc. has increased its ownership in NantPro Biosciences LLC following the amendment of its related corporate and

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1